Pacira BioSciences Inc (STU:82P)
€ 22.8 -0.60 (-2.56%) Market Cap: 901.83 Mil Enterprise Value: 1.08 Bil PE Ratio: 220.08 PB Ratio: 1.59 GF Score: 75/100

Pacira Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2026 / 07:15PM GMT
Release Date Price: €19.1 (+3.24%)
Hardik Parikh
JPMorgan Chase & Co - Analyst

Hi, everybody. I'm Hardik Parikh at JPMorgan covering large-cap pharmaceuticals. I am pleased to have Frank Lee here, CEO of Pacira. He's going to start off with a presentation, and then we'll end up doing a little Q&A afterwards. Thank you.

Frank Lee
Pacira Biosciences Inc - Chief Executive Officer, Director

Thank you, Hardik, for the invitation. Good morning, all here at JPMorgan and those of you following us online. So let me just kick this off with some forward-looking statements and start out with a quick overview of Pacira. Our mission is to deliver innovative non-opioid pain management therapies to transform lives. And we do that by following some simple guiding principles like keeping the patient at the center, following the science and treating our people well.

10-plus years of leadership in this space, last year, we reported actually early this year for last year, unaudited sales of $726 million, 800-plus employees that are highly engaged around our mission and to date, 18 million-plus

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot